DT 2219ARL

Drug Profile

DT 2219ARL

Alternative Names: DT2219ARL; OXS 1550

Latest Information Update: 25 Feb 2016

Price : $50

At a glance

  • Originator University of Minnesota
  • Developer National Cancer Institute (USA); University of Minnesota
  • Class ADP ribose transferases; Antineoplastics; Bispecific antibodies; Drug conjugates; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B cell lymphoma; Leukaemia

Most Recent Events

  • 23 Feb 2016 Oxis Biotech receives patent allowance for DT 2219ARL in USA
  • 02 Feb 2016 Final efficacy data from a phase I trial in Leukaemia and lymphoma released by Oxis Biotech
  • 23 Nov 2015 Oxis Biotech plans a phase I/II trial for Leukaemia and lymphoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top